This is Me - Control Profile. Are you Dr. Gupta? As we have also enacted with nivolumab, all original studies were every two weeks, but we are using the flat dose every four weeks. Sign up for MD.com. Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at … Please verify insurance information directly with your doctor’s office as it may change frequently. Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma (RCC). That's a good point. Dr. Shilpa Gupta (Dewan) is a Pediatric Endocrinologist in Riverside, CA. Shilpi Gupta, MD at 156 William Street in New York, NY is a NewYork-Presbyterian provider specializing in Hematology-Oncology Liver Cancer Medical Oncology and Internal Medicine. It's always a pleasure chatting with you, and thanks for taking the time and sharing your thoughts and the updates with our audience. Sign up for MD.com. And the primary endpoint was overall survival. https://www.medpagetoday.com/meetingcoverage/ascovideopearls/87345 Dr. Gupta is affiliated with James A Haley Veterans Hospital and … 4.9. OVERVIEW Dr. Gupta graduated from the Lady Hardinge Medical College in 2001. Or do you think that they're interchangeable enough that practices that have more familiarity with one of the other agents could use that as maintenance therapy? What are you most excited about? Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. Ashish Kamat: 45% of 53%. Languages. do not copy or download content without artist’s consent. Se especializa en cánceres genitourinarios y tiene una vasta experiencia en inmunoterapia en su práctica profesional y como parte de ensayos clínicos. Shilpa Gupta, MD, es un oncólogo que se especializa en el cáncer genitourinario y trabaja en el Department of Solid Tumor Oncology en el Cleveland Clinic Taussig Cancer Institute. Correct. Dr. Shilpa Gupta graduated from Other in 2001. According to Gupta, preliminary safety data is needed for triplet regimens in RCC. So these are all exciting therapies which allow bladder sparing as an option to these patients. Learn about Dr. Shilpa Gupta, an internist & hematologist / oncologist in Tampa, FL & Minneapolis, MN. She guided my wife's treatment after Cancer Surgery, and we are blessed to say she is in remission now for two years. And neither was the interim overall survival, in the intention-to-treat population. Her current practice location is 7117 Brockton Avenue, Riverside, California.You can reach out to her office (for appointments etc.) About Shilpa Gupta MD Dr. Gupta graduated from the Lady Hardinge Medical College in 2001. Dr Shilpa Gupta, MD is a medicare enrolled "Pediatrics - Pediatric Endocrinology" physician in Riverside, California. We know that based on the KEYNOTE-057, pembrolizumab is approved in this setting, and the treatment complete response rate with that is 41%. Moving on to adjuvant immunotherapy approaches in muscle-invasive bladder cancer. Now, this has been great, a great discussion and lots more I could ask you, but in the interest of time, let me ask you one last question. Shilpa Gupta, DO. This is the study's schema, it did not meet the primary piece specified endpoint, but interestingly, the three month CIS patient complete response rate was 42%. Thanks for the opportunity for sharing the key ASCO updates. Ashish Kamat: Six-week dosing. Shilpa Gupta: Yeah, that's a great question, Ashish. She has hospital affiliations with Cleveland Clinic and Akron General Medical Center. Find Dr. Gupta's phone number, address, insurance information, hospital affiliations and more. The CHECKMATE-274 trial is again, similar setting, randomization to nivolumab versus observation, and the primary endpoint is disease-free survival in PD-L1 positive patients and all patients. Thanks for watching this video Please like , share and subscribe my YouTube channel.. She has indicated that she accepts telehealth appointments. Trying to find Shilpa Gupta? A quick question about the dosing schedule. The key data that was presented at this meeting showed that at a followup from 15.9 months, only about 8% of patients had relapsed. Her credentials are: MD, MBBS.She lists the following medical group affiliations: Fairview Health Services.Her hospital privileges include: University Of Minnesota Medical Center, Fairview. Patients received ipilimumab loading dose, followed by Ipi Nivo, and one dose of nivolumab. And this shows comparable results. Locations {{locAOne}} {{locATwo}} {{locHrMsg}} More Hours---LOCATION DETAILS. We saw the study, NABUCCO, that was presented at ASCO this year, the updated bio market analysis, and clinical follow-up. And the primary analysis populations were all intention-to-treat patients, as well as PD-L1 positive population. School of Fine Arts in 1997. Shilpa Kumta, MD. And in the PD-L1 positive population, the results were even more pronounced. This was the primary analysis from the Phase III randomized trial of adjuvant atezolizumab versus observation in high risk muscle-invasive urothelial carcinoma. Correct? 44 patient ratings, 5 patient comments Specialties. Shilpa Gupta: Six-week dosing. Education & Training. I appreciate the opportunity. Do you have any concerns or any words of caution for people that are extrapolating results from one study to a different dosing schedule? But other than that, platinum-based chemotherapy is our treatment of choice. And the plenary presentation this year was the JAVELIN 100 study, presented by Dr. Tom Powles. In fact, it was presented last year at ASCO. Previously an ENT surgeon, she found her true passion teaching parents, caregivers and teachers the skills necessary to create “happy” families. In the rare circumstance where they cannot get carboplatin, we treat them with single-agent immunotherapy, or if they have high PD-L1 expression in their tumors, and they are cisplatin-ineligible, then they also meet the criteria. Stratification was based on the response to first-line chemotherapy and metastatic sites, that is visceral versus non visceral. And very encouraging clinical results were shown: complete responses in 46% patients, and down-staging in around 58% of patients. 469.764.8000. And there's a combination trial of nivolumab and a CD122 agonist, NKTR-214, versus cystectomy in cisplatin-ineligible patients. COPYRIGHT © 2002 - 2021 DIGITAL SCIENCE PRESS, INC. Login to update email address, newsletter preferences and use bookmarks. She works in Cleveland, OH and specializes in Genitourinary. Female. Last year, I touched upon the key study that was presented in the BCG-unresponsive non-muscle invasive bladder cancer. So this is the study design, any patient who got first-line platinum-based chemotherapy, either carboplatin or cisplatin, and did not have progressive disease, was enrolled in this study, was eligible, with unresectable locally advanced or metastatic urothelial cancer. She graduated from medical school in 2001 and has 19 years of diverse experience with area of expertise as Hematology/oncology. Ashish Kamat: And since many of the studies were actually done before the six-week schedule was established. Languages Spoken: English. Correct? View the profiles of people named Shilpa Gupta. With overall survival, not reached in avelumab and best supportive care arm, and 17 months in the best supportive care arm. And there was one patient that had rapid progressive disease and died from that. The progression-free survival was also significantly better with avelumab and best supportive care. Cincinnati Children's Hospital Medical Center Fellowship, Pediatric Endocrinology, 2005 … If you follow [inaudible] evidence, you obviously have to stick with the data that was presented in Tom Powles' study. https://www.dupagemedicalgroup.com/physicians/shipra-gupta-md Let me have you put on your predictive hat and maybe you could tell us what you predict will be the breaking news when it comes to bladder cancer therapies at ASCO 2021. Specialty Endocrinology / Diabetes Pediatrics Pediatric Endocrinology Shilpa Gupta, MD, MBBS is a medicare enrolled "Internal Medicine - Hematology & Oncology" physician in Minneapolis, Minnesota. But if he were to follow level one evidence, I think the label is only for avelumab, and that is what we should stick to when possible. Photos | Summary | Follow. Ashish Kamat: Thank you so much, Shilpa. Ashish Kamat: That was great, Shilpa, thank you so much for doing this. So these trials are really interesting, and over the next few years will provide insights on where immunotherapy stands alone, or in combination in neoadjuvant setting.